As detailed above, the broad immunomodulatory properties of KIs, combined with the impressive progress in understanding cancer pathophysiology and the development of new immunotherapeutic approaches, sets us up for improving cancer patient treatments and outcomes. The gene discussed is UHMK1; the disease is cancer.